EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice

•We established gefitinib-resistant lung-cancer mouse models in immunocompetent mice.•The resistant tumors develop secondary resistant EGFR mutations such as EGFR T790M.•Osimertinib inhibits the growth of gefitinib-resistant lung cancers in C57BL/6 J mice.•The gefitinib-resistant lung cancers develo...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2019-10, Vol.136, p.86-93
Hauptverfasser:	Higo, Hisao, Ohashi, Kadoaki, Makimoto, Go, Nishii, Kazuya, Kudo, Kenichiro, Kayatani, Hiroe, Watanabe, Hiromi, Kano, Hirohisa, Ninomiya, Kiichiro, Hotta, Katsuyuki, Maeda, Yoshinobu, Kiura, Katsuyuki
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired resistance EGFR mutations NSCLC Osimertinib Transgenic mice
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!